TAS-102 + bevacizumab + irinotecan

TAS-102 + bevacizumab + irinotecan is a combination regimen used primarily as a second-line therapy for metastatic colorectal cancer, particularly in patients who have progressed after standard first-line treatments such as oxaliplatin and fluoropyrimidines. TAS-102 is an oral antimetabolite composed of trifluridine and tipiracil; trifluridine incorporates into DNA, causing dysfunction and cell death, while tipiracil inhibits thymidine phosphorylase to maintain effective levels of trifluridine. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding and replication, leading to cell death. This combination has demonstrated antitumor activity with manageable toxicity profiles in phase I/II studies for metastatic colorectal cancer refractory to first-line therapies[1][2][5].

Brand names

Lonsurf (for TAS-102)Avastin (for bevacizumab)Campto (for irinotecan)

Other names

trifluridine/tipiracil + bevacizumab + irinotecan